Related references
Note: Only part of the references are listed.Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events
Heinz Laeubli et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Safety of influenza vaccination in patients undergoing immunotherapy treatment for advanced cancer
Curtis Robert Chong et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Impact of the influenza vaccination on cancer patients undergoing therapy with immune checkpoint inhibitors (ICI).
Ragisha Gopalakrishnan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
Julia Escandon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Safety and efficacy of concurrent administration of influenza vaccine in patients undergoing anti-PD-1 immunotherapy.
Dimitra Konstantinos Kanaloupitis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Serologic response and clinical efficacy of influenza vaccination in children and young adults on chemotherapy for cancer
Daniel K. Choi et al.
PEDIATRIC BLOOD & CANCER (2016)
PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses
Patrick J. Medina et al.
PHARMACOTHERAPY (2016)
Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe
P. Perez-Romero et al.
CLINICAL MICROBIOLOGY AND INFECTION (2015)
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy
Ninh M. La-Beck et al.
PHARMACOTHERAPY (2015)
Practical review of immunizations in adult patients with cancer
Ella J. Ariza-Heredia et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Inflammatory responses to trivalent influenza virus vaccine among pregnant women
Lisa M. Christian et al.
VACCINE (2011)
Epidemiology and outcomes of serious influenza-related infections in the cancer population
CD Cooksley et al.
CANCER (2005)
Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy
M Zignol et al.
CANCER (2004)
Share Paper
